Medicine and HealthNature Medicine
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
D. H. Ryan, I. Lingvay, et al.
This analysis of the SELECT trial reveals how semaglutide significantly aids weight loss in patients with established cardiovascular disease and obesity, achieving a remarkable mean reduction of 10.2% over 4 years. Conducted by a team of experts including Donna H. Ryan and Ildiko Lingvay, this groundbreaking research underscores the clinical effectiveness of semaglutide in various demographics.
Related Publications
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Medicine and Health
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
D. H. Ryan, I. Lingvay, et al.
Medicine and Health
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
H. M. Colhoun, I. Lingvay, et al.
Medicine and Health
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
J. F. E. Mann, P. Rossing, et al.
Medicine and Health
Effects of Mediterranean diet during pregnancy on the onset of overweight or obesity in the offspring: a randomized trial
S. Coppola, L. Paparo, et al.
